Invion Limited (IVX) is a life-sciences company at the forefront of medical innovation. Their focus is on transforming Photodynamic Therapy (PDT) into a powerful tool for developing novel and effective treatments. PDT has the potential to combat not just cancer, but also atherosclerosis and infectious diseases. Invion is leading the global charge in researching and developing Photosoft technology, a promising advancement in PDT. They hold the exclusive rights to license and distribute Photosoft technology in Australia and New Zealand, positioning themselves as a key player in bringing this revolutionary treatment to patients in these regions.